🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Xiyuan Hospital of China Academy of Chinese Medical Sciences clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Xiyuan Hospital of China Academy of Chinese Medical Sciences as lead sponsor. Synced 26 Sep 2026
6Current trials
3Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Xiyuan Hospital of China Academy of Chinese Medical Sciences is the lead sponsor of 6 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Songling Xuemaikang and Xuesaitong soft. The most-studied condition is Non-erosive Reflux Disease (NERD).

ClinicalTrials.gov trials by status

  • Recruiting350%
  • Not yet open350%

Trials by phase

  • Not applicable233%
  • Phase 1117%
  • Phase 2117%
  • Phase 3117%
  • Phase 4117%
01

Clinical trials sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Study on the Effectiveness and Mechanism of Tong-Xie-Yao-Fang in Treating Diarrhea-predominant Irritable Bowel Syndrome
NCT06737666 · ClinicalTrials.gov ↗ · Diarrhea-predominant Irritable Bowel Syndrome
Phase 1 Recruiting 2023-05 China
Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne
NCT06311890 · ClinicalTrials.gov ↗ · Acne, Photodynamic Therapy
Phase 2 Recruiting 2024-02 China
Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial
NCT06093932 · ClinicalTrials.gov ↗ · Hypertension,Essential
Phase 4 Recruiting 2024-04 China
Clinical Efficacy Evaluation of Chaizhi Hewei Decoction in the Treatment of Non-Erosive Reflux Disease With Liver-Stomach Disharmony Syndrome
NCT07518420 · ClinicalTrials.gov ↗ · Non-erosive Reflux Disease (NERD)
Not applicable Not yet open 2026-05 China
Efficacy and Mechanistic Evaluation of Hewei Anchang Formula for Overlapping Gastrointestinal Symptoms in Patients With Coexisting Functional Dyspepsia and Diarrhea-Predominant Irritable Bowel Syndrome
NCT07715760 · ClinicalTrials.gov ↗ · Functional Dyspepsia, Irritable Bowel Syndrome With Diarrhea
Not applicable Not yet open 2027-01 China
Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol
NCT06845254 · ClinicalTrials.gov ↗ · Acute Coronary Syndrome
Phase 3 Not yet open 2025-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Xiyuan Hospital of China Academy of Chinese Medical Sciences trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Xiyuan Hospital of China Academy of Chinese Medical Sciences trials

8 conditions
Non-erosive Reflux Disease (NERD)1Diarrhea-predominant Irritable Bowel Syndrome1Functional Dyspepsia1Irritable Bowel Syndrome With Diarrhea1Acne1Photodynamic Therapy1Acute Coronary Syndrome1Hypertension,Essential1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China63

A trial with sites in more than one country appears in each of those registers.

05

Questions about Xiyuan Hospital of China Academy of Chinese Medical Sciences trials

How many clinical trials does Xiyuan Hospital of China Academy of Chinese Medical Sciences sponsor?

Xiyuan Hospital of China Academy of Chinese Medical Sciences is the lead sponsor of 6 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Xiyuan Hospital of China Academy of Chinese Medical Sciences trials recruiting?

Yes. 3 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Xiyuan Hospital of China Academy of Chinese Medical Sciences testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Songling Xuemaikang (1) and Xuesaitong soft (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.